-+ 0.00%
-+ 0.00%
-+ 0.00%

NEKTAR THERAPEUTICS SHARES DOWN 2.4% PREMARKET AFTER ITS AUTOIMMUNE DISORDER DRUG MISSES MAIN GOAL IN MID-STAGE STUDY

Reuters·12/16/2025 13:43:07

Please log in to view news